How to Maintain GxP Audit Coverage When You Don’t Have an In-House Audit Team
GxP audit coverage is not optional. It is a fundamental component of a functioning quality system, a regulatory expectation, and in many cases a contractual requirement from partners, sponsors, and licensing organisations. The absence of an in-house audit team does not remove that requirement. It changes how you meet it.
For a significant proportion of organisations in the pharmaceutical, biotech, and medical device sectors, a dedicated internal audit function is not a realistic operating model. Early-stage companies, virtual organisations, and leaner commercial businesses routinely manage their quality obligations without the headcount to sustain a full-time audit programme. The question is not whether audit coverage is needed. It is how to structure it so that it is genuine, proportionate, and defensible under regulatory scrutiny.
This article sets out how to approach GxP audit coverage without an in-house team: what the regulatory expectation actually requires, what models work in practice, and where specialist support adds the most value.
1. What the Regulatory Expectation Actually Requires
The GxP framework, across GMP, GCP, GLP, and GDP, requires organisations to have a functioning audit programme. The specific requirements vary by regulation and guidance, but the underlying expectation is consistent: you must be able to demonstrate that your quality system is being assessed against defined standards, that deviations are being identified and addressed, and that the programme is documented, risk-based, and proportionate to your activities.
What the regulations do not require is that the function is performed by permanent employees. ICH Q10, the EU GMP guidelines, and FDA 21 CFR Part 211 all allow for the use of contracted or outsourced audit resource, provided that the oversight and accountability remain within the organisation. The quality system belongs to you. The audit programme can be resourced externally.
The critical distinction is between outsourcing the activity and outsourcing the responsibility. Responsibility for audit coverage, for reviewing findings, for driving corrective action, and for demonstrating programme effectiveness cannot be delegated to a third party. The execution can be. Understanding this distinction is fundamental to structuring a compliant and defensible audit programme without in-house resource.
The Regulatory Position
ICH Q10 and EU GMP Chapter 1 both position the audit programme as a management responsibility, not a functional one. The obligation sits at the organisational level. How that obligation is resourced is a matter of operational design, not regulatory requirement.
2. The Risk of Doing Nothing
Before addressing how to structure audit coverage without an in-house team, it is worth being direct about the risk of not doing so. Organisations that allow their audit programme to lapse, or that have never established one, are exposed on multiple fronts.
Regulatory exposure
An absence of documented audit activity is a finding in its own right. MHRA and FDA inspectors routinely review audit records as part of a GMP inspection. An organisation that cannot produce a risk-based audit schedule, completed audit reports, and evidence of CAPA follow-through will receive a finding regardless of the quality of the underlying operations being audited. The programme itself is the subject of assessment.
Supplier and vendor risk
Organisations that do not audit their contract manufacturers, testing laboratories, and critical suppliers are carrying undisclosed risk in their supply chain. Regulatory expectation is clear: you are responsible for the quality of what your suppliers deliver. Qualification without ongoing oversight is not a compliant model. Issues that surface at inspection, in batch testing, or at release that could have been identified through a supplier audit programme create both quality and regulatory consequences.
Commercial and partnering risk
Licensing partners, co-development organisations, and institutional investors increasingly assess quality system maturity as part of due diligence. An audit programme that exists only on paper, or does not exist at all, is a red flag in any serious due diligence process. It signals broader quality system weakness and can affect deal terms or outcomes.
Is Your Audit Programme Fit for Scrutiny?
TDP conducts independent audit programme assessments for organisations at every stage of development. We review your current audit coverage, identify gaps against regulatory expectation, and provide a practical roadmap for establishing or strengthening your programme.
3. Structuring an Outsourced Audit Programme That Works
An outsourced audit programme is not simply a matter of engaging an external auditor to conduct audits on your behalf. Done well, it is a structured programme with defined scope, a risk-based schedule, clear accountabilities, and documented oversight. Done poorly, it is a series of disconnected audit events that satisfy no one and inform nothing.
The following elements are essential to a compliant and effective outsourced audit programme.
A documented audit strategy
The programme must begin with a written audit strategy that defines scope, frequency, risk criteria, and the categories of activity covered. This document demonstrates to a regulator that the programme is planned and proportionate, not reactive. It should cover internal process audits, supplier and vendor audits, and any regulatory or sponsor audits that the organisation is subject to.
A risk-based audit schedule
Not all audit activities carry equal risk. A contract manufacturer producing a late-phase clinical trial material carries different risk to a packaging supplier. A CRO managing primary efficacy endpoints carries different risk to a data management vendor. The audit schedule should reflect this, allocating resource to the highest-risk relationships and activities, with frequency calibrated to risk level, performance history, and the criticality of the relationship to your programme.
Clear accountability within the organisation
Someone within your organisation must own the audit programme. This does not require a full-time quality professional: in many lean organisations it is the QP, the Head of Quality, or a senior regulatory lead. What it requires is that the person responsible for the programme has sufficient authority to act on findings, to commission CAPA activity, and to escalate systemic issues to leadership. The external auditor executes. The internal accountable person governs.
Robust audit reporting and CAPA follow-through
Audit reports must be documented, reviewed, and acted upon within defined timescales. CAPA activity arising from audit findings must be tracked to closure and verified for effectiveness. A regulator reviewing your audit programme will look for evidence that findings were taken seriously, that root causes were addressed, and that the programme generated genuine quality improvement. A folder of audit reports with no evidence of action is worse than no programme at all.
Periodic programme review
The audit schedule should be reviewed at least annually against the risk profile of the organisation. New suppliers, new geographies, programme phase changes, and regulatory developments all affect where audit resource should be focused. A static schedule that does not respond to change is not a risk-based programme.
A Note on Auditor Competence
The effectiveness of an outsourced audit programme depends entirely on the competence and experience of the auditors conducting it. An auditor with deep experience in your therapeutic area, product type, and regulatory market will identify issues that a generalist will miss. When selecting external audit resource, prioritise relevant expertise over cost.
4. What Types of Audit Does Your Programme Need to Cover?
GxP audit coverage spans several distinct categories, and the right programme design depends on your organisation’s specific activities, stage of development, and supply chain complexity. Most organisations operating without an in-house team will need coverage across some or all of the following.
Supplier and vendor qualification audits
Qualification audits establish that a new supplier or vendor meets the standards required before they are engaged. For contract manufacturers, testing laboratories, and other GxP-critical suppliers, this is a regulatory requirement. The audit must be conducted before the relationship begins, with findings resolved and documented prior to approval.
Periodic supplier surveillance audits
Qualification is not a one-time event. GxP expectation requires ongoing surveillance of approved suppliers, with frequency proportionate to risk. High-criticality suppliers typically require annual audits. Lower-risk vendors may be reviewed less frequently, with desktop audits or questionnaire-based assessments supplementing on-site visits.
Internal process audits
Internal audits assess your own quality system processes against applicable regulations and standards. For organisations without dedicated internal auditors, these are frequently the most neglected element of the audit programme. An independent external auditor conducting internal audits provides the objectivity that a self-assessment cannot, and produces findings that are credible to an inspector.
For-cause audits
For-cause audits are triggered by specific quality events: a supplier deviation, a complaint pattern, a batch failure, or intelligence that suggests a quality risk. The ability to mobilise a for-cause audit quickly is an important element of a mature quality system. Organisations without an in-house team need an established relationship with an external auditor who can respond at short notice when the need arises.
Mock regulatory inspections
A mock inspection is a specialist form of internal audit that simulates an MHRA or FDA inspection. It assesses your systems, documentation, and people against current inspection expectations, identifies vulnerabilities before a regulator finds them, and provides the inspection experience that prepares your team for the real thing. For organisations approaching a first regulatory inspection, a well-conducted mock inspection is one of the highest-value audit activities available.
TDP’s GxP Auditing Services
TDP provides the full range of GxP audit services for organisations that do not have an in-house audit function. From supplier qualification and periodic surveillance through internal process audits and mock inspections, our auditors bring direct regulatory experience and deep therapeutic area knowledge to every engagement.
5. The Case for an Embedded or Retained Audit Model
For organisations that need consistent audit coverage across a programme, a transactional model of engaging an auditor on a per-audit basis has limitations. Costs are harder to predict, mobilisation takes time, and the auditor conducting an audit is not always the same person each time. Consistency of audit approach and knowledge of your programme builds over time and is difficult to replicate with a purely transactional model.
An embedded or retained audit model addresses these limitations. Under this model, a named external auditor or audit team is engaged on a retained basis to provide defined audit coverage over a fixed period. The benefits are significant:
• Programme continuity: the same auditors develop genuine knowledge of your organisation, your supply chain, and your quality history, making each successive audit more effective.
• Predictable cost: a retainer model converts variable audit expenditure into a fixed planned cost, which is easier to budget and to justify internally.
• Faster mobilisation: an auditor already familiar with your programme can execute a for-cause or urgent audit with minimal ramp-up time.
• Stronger regulatory credibility: a documented, continuous audit relationship is more defensible under inspection than a series of ad hoc engagements.
For early-phase and mid-size biotech organisations, this model effectively provides the functional equivalent of an in-house audit team without the overhead of permanent headcount.
6. Integrating External Audit Resource With Your Quality System
An outsourced audit programme only adds value if it is genuinely integrated into your quality system. External audit findings must flow into your CAPA process with the same rigour as any other quality event. Audit reports must be reviewed and signed off by the appropriate internal authority. Trends across audits must be tracked and reported to senior management. The programme must be documented in your Quality Management System and referenced in your Quality Manual or equivalent.
The failure mode in many outsourced audit programmes is the gap between the audit activity and the quality system. Audits happen, reports are produced, and then the findings sit in a folder rather than driving meaningful improvement. This is not a compliance programme. It is an administrative exercise, and an experienced regulator will identify it as such.
Effective integration requires three things: a clear owner within the organisation who takes accountability for the programme, a defined process for converting audit findings into CAPA activity, and a regular management review that covers audit programme performance alongside other quality indicators.
What Regulators Look For
An MHRA or FDA inspector reviewing your audit programme will look beyond the audit reports themselves. They will look for evidence that findings were reviewed at an appropriate level, that CAPA was genuinely implemented, and that the programme informed management decision-making. Audit activity without a visible quality system connection does not satisfy the regulatory expectation.
7. Getting the Model Right for Your Stage of Development
The right audit model varies significantly depending on where your organisation is in its development journey. A pre-clinical biotech with a handful of third-party relationships has different audit requirements to a Phase III sponsor managing a complex international supply chain, or a commercial organisation maintaining ongoing surveillance across an approved product portfolio.
Pre-clinical and early Phase I
At this stage, audit activity is typically focused on qualifying key suppliers and establishing the foundations of an audit programme that will scale. The immediate priority is ensuring that the organisations manufacturing and testing your material are qualified and that that qualification is documented. A small number of targeted supplier audits, supported by a written audit strategy that demonstrates proportionate risk-based thinking, is typically appropriate.
Phase II and Phase III
As the programme scales, audit demands increase. More suppliers, more complex supply chains, more regulatory markets, and the proximity of regulatory submissions all increase the stakes. A retained external audit model becomes increasingly valuable at this stage, providing consistent coverage without the cost and lead time of building an internal team. Mock inspections become a genuine priority as a first regulatory inspection approaches.
Commercial organisations
Commercial-stage organisations have ongoing regulatory commitments that require a structured, sustainable audit programme. The frequency and scope of supplier surveillance increases. Internal process audits must be conducted against commercial-stage expectations. The audit programme must be mature enough to generate real quality intelligence and to satisfy inspector scrutiny. For leaner commercial organisations, a retained external audit function provides the continuity and expertise of an in-house team without the fixed cost.
Final Thought
The absence of an in-house audit team is a resourcing reality for many organisations in the pharmaceutical sector. It is not a reason to have an inadequate audit programme. The regulatory expectation is clear, the commercial and quality risks of under-auditing are real, and the models for delivering genuine GxP audit coverage without permanent headcount are well-established and widely used.
The organisations that manage this well are those that treat their outsourced audit programme with the same rigour they would apply to an internal function. A documented strategy, a risk-based schedule, clear internal accountability, genuine CAPA follow-through, and a consistent external audit partner who understands your business: these are the components of a programme that holds up under scrutiny.
If your current audit coverage does not meet that standard, the time to address it is before an inspection, a due diligence process, or a quality event makes the gap visible.
Build a Compliant Audit Programme With TDP
TDP works with pharmaceutical and biotech organisations at every stage of development to design, establish, and deliver GxP audit programmes that are proportionate, compliant, and genuinely effective. Whether you need a single qualification audit or a retained audit partner to provide ongoing programme coverage, we have the expertise and capacity to support you.